population that require lung transplantation.4 How¬ ever, it is unknown whether CF lung transplant recipients who had evidence of respiratory coloniza¬ tion with Aspergillus prior to transplantation are at an increased risk of developing postoperative inva¬ sive aspergillosis following the initiation of long-term immunosuppression. Therefore, we retrospectively reviewed our center s experience with those CF lung recipients who were known to have Aspergillus on culture of the sputum prior to transplantation with respect to the development of invasive aspergillosis following successful transplantation.
Materials and Methods
Between April 1991 and February 1996, 54 patients with CF received double lung or double lobar transplantation at our institution for end-stage pulmonary disease. A total of 31 CF recipients had serial cultures of sputum for bacteria and fungi (approximately every 6 to 8 weeks) while awaiting their trans¬ plant, had successful grafting, and survived a minimum of 14 days following the procedure. None of the CF recipients who died prior to postoperative day (POD) 14 had infections with Aspergil¬ lus. Of these 31, 11 were male and 20 were female with the average age at the time of transplant being 32 years (median, 30 years). All of the CF recipients had chronic pulmonary infections with Pseudomonas prior to transplantation.
Fifty-three double lung recipients contemporaneously receiv¬ ing allografts for a variety of indications were utilized for comparison and designated the non-CF group. This group consisted of 25 male and 28 female patients with the mean age at the time of transplant being 41 years (median, 42 years). The pretransplant diagnosis in this recipient group included the following: Eisenmenger's syndrome (n = 21), primary pulmonary hypertension (n 12), chronic obstructive lung disease (n = 10), arantitrypsin deficiency (n = 4), pulmonary fibrosis (n = 3), bronchoalveolar carcinoma (n = 1), Munier-Kuhn syndrome (n = 1), and obliterative bronchiolitis (n = 1). Recipients receiv¬ ing allografts for bronchiectasis (n = 7) and dysmotile cilia syndromes (n = 1) were excluded from the non-CF group. The recipients in these latter two categories were not included in the CF group because their underlying pathophysiology is not iden¬ tical to CF (a group in which the incidence of Aspergillus colonization has been better defined). Likewise, these recipients were not included in the non-CF group because, unlike the other disorders in this group, they were associated with infections. To better compare the posttransplant morbidity from Aspergillus in this preliminary investigation, it was decided to initially compare the CF recipients (where Aspergillus colonization prior to trans¬ plantation is more prevalent) with a group of nonseptic lung disorders (where Aspergillus colonization is not expected or well defined). All of the recipients in the non-CF group also had serial cultures of sputum for bacteria and fungi while awaiting their transplant procedure. Engraftment of the donor organs was performed utilizing the bilateral sequential technique with endto-end bronchial anastomoses as previously described.5 Proce¬ dures performed for recipients of pulmonary lobes from living related donors were performed utilizing a telescoping bronchial anastomosis secondary to the relative small size of the donor bronchus.6
Immediately following transplantation, routine immunosup¬ pression was employed utilizing standard regimens consisting of cyclosporine or tacrolimus with azathioprine and corticosteroids (initially IV methylprednisolone and later oral prednisone). All of the CF recipients were empirically treated for the first 10 to 14 PODs with two antipseudomonal systemic antibiotics. Recipients in the non-CF group received empiric systemic antibiotic therapy with clindamycin and ceftazidime for the first 7 to 10 postoper¬ ative days unless preoperative cultures of sputum suggested organisms that required specific antimicrobial coverage. No recipient received empiric systemic or aerosolized antifungal therapy. Likewise, recipients found to have Aspergillus in respi¬ ratory secretions following transplantation without accompanying tissue invasion were not routinely treated with antifungal agents.
Surveillance bronchoscopy with transbronchial biopsies was performed routinely at a minimum of every 12 weeks during the first postoperative year, every 16 weeks during the second year, and every 36 to 52 weeks thereafter. As determined by the physician, bronchoscopy was additionally performed for any deterioration in clinical status of the recipient manifested by cough, dyspnea, and/or decline in spirometric values. The aver¬ age postoperative surveillance time for the CF group was 634 days (median, 506 days; range, 18 to 1,815 days) and 731 days (median, 750 days; range, 18 to 1,800 days) for the non-CF group. Endobronchial biopsies were performed for visual abnormalities noted by the physician. Grocott tissue stains to assess for fungal elements were performed on the biopsy material. All biopsy specimens were interpreted by a skilled pulmonary pathologist. BAL was performed as a routine part of each bronchoscopic procedure. If the recipient was receiving mechanical ventilatory support, the bronchoscope was passed via the endotracheal or tracheostomy tube. If the patient was spontaneously breathing, the bronchoscope was passed either through the nose and nasopharynx or the mouth and oropharynx. One percent lido¬ caine was used as regional anesthesia of the glottic structures. Suction was not applied to the bronchoscope until the tip was wedged into a subsegmental airway.usually in the right middle lobe or lingula. Two hundred milliliters of sterile saline solution was introduced into the airway in 50-mL aliquots. Suction was then employed, and after each aliquot, as much of the saline solution as could be recovered was aspirated from the airway into a sterile suction trap. Once the saline solution lavage fluid was recovered, this BAL fluid (BALF) was processed by an experi¬ enced technician. All recovered BALF, including the first recov¬ ered aliquot, was separated into two samples of approximately equal volume. After centrifugation of each sample, the resulting cell pellet was recovered. One pellet was resuspended in buffer solution and appropriate cell counts were obtained. The second sample with its cell pellet was forwarded to a microbiology and a cytology laboratory where the fluid was cultured using standard bacterial and fungal growth media. Appropriate staining of the BALF was performed utilizing Gram's and calcoflour white stain.
Definitions
A positive culture for Aspergillus denotes the isolation of any species in this genus (ie, Aspergillusfumigatus, Aspergillus niger, Aspergillus flavus). Fungal infection was defined solely on the bases of allograft histology revealing characteristic invasive fungal elements. With respect to infection, biopsy material was graded as either pneumonia (alveolar airspace infiltration) or bronchitis (bronchial mucosal or submucosal infiltration). Those recipients with positive BALF or sputum cultures for Aspergillus without accompanying characteristic histologic changes on biopsy mate¬ rial were considered to be simply "colonized" with the fungus. Statistical Analysis Data are expressed as mean or median unless otherwise stated. The x2 and Fisher's Exact Tests were employed for comparisons between nominal variables utilizing 2X2 contingency tables. Means between study groups were compared using the Student's t test. The Mann-Whitney U test was used to compare all unpaired data. A significant difference was determined at p < 0.05. Figure 1 summarizes the course of the 31 CF lung recipients. Of these 31 recipients, 7 (22%) were noted to have Aspergillus isolated on at least one culture of sputum prior to transplantation. Following transplantation, 15 of the 31 recipients (48%) were found to have Aspergillus in culture of sputum or BALF by median POD 23 (range, 3 to 1,142 days).
Results
Included in these 15 recipients were 4 of the 7 CF recipients (57%) identified with Aspergillus prior to transplantation. Of the 24 CF recipients without Aspergillus isolated prior to transplantation, 11 re¬ cipients (46%) were found to have the fungus in the respiratory tract following transplantation.
Four of the 15 CF recipients (27%) with Aspergil¬ lus isolated following transplantation had histologic evidence of tissue-invasive disease identified on bi¬ opsy material. One of these recipients developed a bronchitis secondary to Aspergillus on POD 1,142 in association with a pneumonitis secondary to cyto¬ megalovirus. This recipient did not have Aspergillus isolated on culture of sputum prior to transplanta¬ tion. The remaining three recipients each developed tissue-invasive disease involving the bronchial anas¬ tomosis early in the postoperative period (POD 15, 23, and 58). In each case, the infection was second¬ ary to A fumigatus. Each of these three recipients had Aspergillus isolated from culture of sputum prior to transplantation. Two of these three recipients also had fungal cultures of their native lungs at the time of the transplant procedure that revealed A fumiga¬ tus. The third recipient's species of Aspergillus was not able to be identified on culture of the sputum prior to transplantation. Two Therefore, of the 7 CF recipients with Aspergillus prior to transplantation, 3 (43%) developed early postoperative infections involving the bronchial anastomosis as compared with the one late postop¬ erative infection in the group of 24 CF recipients (4%) without Aspergillus prior to transplantation. The prevalence of infection in the CF recipients having Aspergillus prior to transplantation was sig¬ nificantly greater than the prevalence of infection in the CF recipients without Aspergillus prior to trans¬ plantation (p = 0.02, Fisher s exact p value) (Fig 4) . logic evidence of tissue-invasive disease, 1 with pneumonia and 2 with bronchitis (POD 123, 188, and 870), but no infections of the bronchial anasto¬ mosis. The prevalence of invasive disease in these non-CF recipients was no greater than in the CF recipients (x~0.86, p = 0.36) ( Fig 6) . Both fungal and routine bacterial cultures were performed on the sputum in both recipient groups prior to transplantation. The mean number of rou¬ tine cultures obtained in the CF recipients was 7.13 ± 6.16, while the mean number of fungal cul¬ tures was 1.42 ± 1.54. The total number of sputum cultures obtained prior to transplantation was signif¬ icantly greater in the CF recipient group (X = 8^55 ± 6.81) compared with the non-CF recip¬ ients (X = 1.15 ± 2.69) (p < 0.001, Student's t test).
Aspergillus Infections in CF Lung
Fifty-three contemporaneous patients received double lung transplantation for a variety of nonseptic lung disorders. Figure 5 summarizes the course of these non-CF recipients. None of these recipients had Aspergillus isolated from cultures of sputum prior to transplantation. Following transplantation, 21 of these recipients (40%) had Aspergillus isolated from sputum or BALF during postoperative surveil¬ lance. The prevalence of postoperative isolation of Aspergillus in this group did not differ significantly from the CF recipients (x2 = 0.43, p = 0.51). The median time to isolation of Aspergillus in this recip¬ ient group was POD 292 (range, 7 to 1,160 days) and was significantly greater than the time to isolation in the CF recipients (p = 0.02, Mann-Whitney U). Three of these 21 recipients (14%) developed histo- Figure 3 . Postmortem examination of the lung allograft in a recipient with Aspergillus infection of the bronchial anastomosis who died of massive hemoptysis. The probe (large arrow) is through the defect in the bronchus leading to the bronchial artery. The anastomotic site is designated by the small arrow.
Discussion
Our experience illustrates two important findings.
First, as with other investigations, we found that colonization of the lower respiratory tract with As¬ pergillus is a common occurrence following lung transplantation; the prevalence does not differ in the CF lung recipients as compared with other lung allograft recipients.7 However, unlike previous inves¬ tigations, we experienced a statistically increased number of bronchial anastomotic infections attribut¬ able to Aspergillus in those CF recipients who had the fungus isolated in their sputum prior to trans¬ plantation.
Aspergillus is a common finding in the respiratory secretions of adult CF patients. Treatment to erad¬ icate the fungus is unnecessary as tissue invasion has rarely been reported to occur. As many as 10% of the adult CF population will experience bronchospasm secondary to allergic bronchopulmonary aspergillosis often coincident with the finding of Aspergillus in the sputum. Aspergillus prior to transplantation. This suggests that those recipients with airway colonization at the time of transplantation have this potential pathogen at the site of a fresh surgical incision. The normal nutrient blood supply to the major bronchi is sup¬ plied by the bronchial arteries that are disrupted during the end-to-end bronchial anastomotic proce¬ dure.5 This may result in transiently devascularized tissue at the surgical site that, in the presence of immediate induction of immunosuppression, pro¬ vides a excellent growth medium for Aspergillus. This early devascularization scenario would be con¬ sistent with the finding that all of these bronchial infections occurred within the first 60 days following transplantation. Furthermore, it has been suggested that the early use of corticosteroids (as has been done in our program) following transplantation may promote infections with Aspergillus in lung trans¬ plant recipients. 15 Macrophages and granulocytes are the major immunoregulatory cells involved in the host defense against fungal infections. It has been demonstrated that corticosteroids suppress macrophage and granulocyte function while no effect has 1326 been noted from the suppression of T-lymphocyte function by cyclosporine.16 Paradowski15 recently reported the experience of the University of North Carolina transplant center with respect to saprophytic infections. She identified 35 of 71 CF transplant recipients (52%) with preop¬ erative airway colonization with Aspergillus. Only one CF recipient developed invasive fungal disease after transplantation. This infection, with Scedosporium apiospermum, initially involved the CNS and later the lung parenchyma. It is unknown whether this recipient was one of those colonized preopera¬ tively. Of note, until recently the induction of immu¬ nosuppression in their program was devoid of corti¬ costeroid use until POD 15. Also, the use of the omental wrap was employed to promote blood flow to the bronchial anastomosis. It is interesting to speculate that one or both of these practices may have contributed to the absence of fungal bronchial anastomotic infections in their series.
Our results are contingent on the accurate identi¬ fication of Aspergillus in the sputum prior to trans¬ plantation and the assumption that this identifies persistent colonization of the lower respiratory tract.
It is possible that our preoperative identification of CF patients with Aspergillus is flawed. Unlike the situation with the bacterium Pseudomonas aeruginosa, it is unknown whether Aspergillus persists in the lower respiratory tract of CF patients following the initial isolation. Once colonized with P aeruginosa, the organism, with very few exceptions, re¬ mains in the lower respiratory tract and can be recovered sequentially on cultures of the spu¬ tum. [17] [18] [19] This is, in part, believed to be secondary to adhesion of carbohydrate moieties in the capsule of the organism with certain receptors on the respira¬ tory epithelium.20 No such epithelial adhesion has been demonstrated with Aspergillus, and whether the organism persists in the lower respiratory tract has not been defined. Those health professionals who routinely care for patients with CF frequently observe Aspergillus in cultures of the sputum that may disappear on subsequent cultures only to reap¬ pear at a later time. It is unknown whether this is related to sputum collection techniques, laboratory culture techniques, or actually represents transient and/or relapsing colonization of the lower respiratoiy tract by the organism. There have been preliminary observations to suggest that culturing of the sputum has a low positive predictive value for identifying those patients who have Aspergillus in the lower respiratory tract.21 It is therefore possible that those recipients identified by culture of sputum as harbor¬ ing Aspergillus in their airway preoperatively may not have had the organism at the time of the transplant procedure. It is unfortunate that our program was not consistent in its the early years in routinely culturing the native recipient lungs for fungal elements. It is known that two of the three recipients with bronchial anastomotic infections had fungal cultures obtained of their native lungs and both showed positive growth of Aspergillus.
Other than cultures of respiratory secretions, it may be possible to identify those CF recipients having Aspergillus prior to transplantation by the use of serologic markers. ABPA is a relatively common occurrence in CF and is typically identified by, among other criteria, an elevated total IgE level, immediate cutaneous reactivity to A fumigatus, and elevated serum IgE or IgG antibodies to A fumiga¬ tus.1 These markers have been used successfully in a CF recipient who had ABPA diagnosed serologically before transplantation and had these markers de¬ crease after transplantation only to rise again with the clinical recurrence of ABPA later in the posttransplant course.22 Elevation of these serologic markers may also be beneficial in predicting As¬ pergillus infections prior to radiographic or culture evidence, and may be useful in monitoring the response to antifungal therapy.2324 Whether the quantity of Aspergillus in the airway prior to trans¬ plantation is relevant to the risk of postoperative infection and whether the degree of elevation of these markers correlates with the quantity of As¬ pergillus is unknown.
Assuming that cultures of the sputum are accurate for identifying those lung transplant candidates har¬ boring Aspergillus in the lower respiratory tract, there arises another potential source of error in our findings. Significantly more cultures of the sputum were obtained in the CF recipients prior to trans¬ plantation as compared with the non-CF recipients. This discrepancy in sampling could fail to accurately identify those non-CF recipients colonized with As¬ pergillus prior to transplantation. However, the lung diseases in the non-CF group were noninfectious disorders and those not typically associated with fungal colonization. Furthermore, the nature of these disorders was such that the subjects did not chronically produce sputum and thus the ability to obtain frequent samples was curtailed.
If cultures of the sputum revealing Aspergillus truly identify those recipients at risk for postopera¬ tive infections, there remains the question of man¬ agement. Long considered the mainstay of antifungal therapy, amphotericin B clearly has some undesir¬ able side effects. Among these, nephrotoxicity is the most worrisome. Both cyclosporine and tacrolimus are significantly nephrotoxic. In addition, any intra¬ operative hemodynamic instability places the recip¬ ient at risk for developing acute tubular necrosis. For these reasons, the prophylactic use of this agent following transplantation in CF recipients with As¬ pergillus can hardly be recommended. Amphotericin B has been used in an aerosolized formulation for the treatment of ABPA in patients with CF.25 Al¬ though there has been some anecdotal evidence of improvement with this therapy, it has not been employed to completely eradicate the fungus and controlled clinical trials of its efficacy have not been performed. Aerosolized amphotericin B has also been employed prophylactically in bone marrow transplant recipients for prevention of fungal pulmo¬ nary infections with some demonstrated success.26 Preliminary investigations into prophylactic use of aerosolized amphotericin B for prevention of fungal pulmonary infections in heart and lung transplant recipients have demonstrated some benefit.27
Of the newer class of azole antifungal drugs, itraconazole has demonstrated in vivo activity against Aspergillus pulmonary infections in immunocompromised patients.2829 Its use in transplant recipients can be complicated by drug interactions with cyclo¬ sporine, tacrolimus, and several other medications frequently employed in this patient population.3031 These interactions, if carefully monitored, generally do not preclude its use. Some transplant centers utilize itraconazole prior to transplantation in those CF candidates with Aspergillus isolated in cultures of sputum with the goal of eradicating or significantly reducing the amount of the fungus in the airway. It is known that the growth of Pseudomonas in the airway of the CF patient is attenuated by the use of systemic antimicrobials but that its eradication is generally not possible.32 There are no corresponding data regarding the use of itraconazole and the erad¬ ication or reduction of Aspergillus in CF patients who have the fungus isolated from sputum. One report has suggested an improvement in the treat¬ ment of ABPA in CF patients by utilizing itracon¬ azole with systemic corticosteroids.33 It was postu¬ lated that the observed benefit of itraconazole may have been secondary to reducing the burden of Aspergillus, although this was not an outcome mea¬ sure of this study. Therefore, at this time, the use of preoperative itraconazole in this patient population with the goal of fungal eradication is unprecedented.
Recently, it has been suggested that lung trans¬ plant recipients who have colonization of their airway secretions with Afumigatus within the first 6 months following transplantation are at increased risk for developing tissue-invasive disease.34 Unfortunately, in this investigation, the identification of tissueinvasive disease was not always heralded by prior recovery of Aspergillus from airway secretions. Therefore, the authors have suggested that empiric anti-Aspergillus therapy for the first 6 months fol¬ lowing transplantation may be beneficial. The basis for this suggestion would be consistent with our observation that most invasive Aspergillus infections occurred before POD 60. As in this previous inves¬ tigation, our cases of tissue-invasive disease also appear to be primarily related to Afumigatus.
In addition to a reduction of systemic immunosup¬ pression, all three of our recipients with endobron¬ chial Aspergillus were treated with a combination of systemic and aerosolized amphotericin B as well as with oral itraconazole. This therapy was successful in two of the three recipients, but only after several weeks of treatment.
In summary, we conclude that the isolation of Aspergillus from the lower respiratory tract is a common occurrence following lung transplantation, and in most cases is not associated with tissueinvasive disease. There is no difference in the prev¬ alence of Aspergillus in airway secretions between CF and non-CF lung recipients. Likewise, there is no difference in the prevalence of tissue-invasive disease secondary to Aspergillus between these groups. However, there is an increase in the number of Aspergillus infections in those CF recipients known to have the fungus in their airway prior to transplantation. These infections tend to have a predilection for the site of the bronchial anastomosis.
Close surveillance of the healing bronchial anasto¬ mosis is therefore crucial in these recipients. 
